| Literature DB >> 11481031 |
I D Nagtegaal1, C A Marijnen, E K Kranenbarg, A Mulder-Stapel, J Hermans, C J van de Velde, J H van Krieken.
Abstract
BACKGROUND: Invasion and metastasis is a complex process governed by the interaction of genetically altered tumor cells and the immunological and inflammatory host response. Specific T-cells directed against tumor cells and the nonspecific inflammatory reaction due to tissue damage, cooperate against invasive tumor cells in order to prevent recurrences. Data concerning involvement of individual cell types are readily available but little is known about the coordinate interactions between both forms of immune response. PATIENTS AND METHODS: The presence of inflammatory infiltrate and eosinophils was determined in 1530 patients with rectal adenocarcinoma from a multicenter trial. We selected 160 patients to analyze this inflammatory infiltrate in more detail using immunohistochemistry. The association with the development of local and distant relapses was determined using univariate and multivariate log rank testing.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11481031 PMCID: PMC35356 DOI: 10.1186/1471-2407-1-7
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Categorical arrangements for the different cell types in 160 rectal cancer patients.
| cell type (antibody) | intratumoral | peritumoral | |||||
| cells / mm2 | % of patients | cells / mm2 | % of patients | ||||
| eosinophils | (EG-2) | n = 159 | n = 140 | ||||
| none/few | 0-10 | 29 | 0-50 | 31 | |||
| moderate | 11-50 | 50 | 51 - 200 | 43 | |||
| many | > 50 | 21 | > 200 | 26 | |||
| neutrophils | (elastase) | n = 160 | n = 152 | ||||
| none/few | 0-5 | 21 | 0 - 75 | 24 | |||
| moderate | 6 - 50 | 54 | |||||
| many | > 50 | 25 | > 75 | 76 | |||
| mast cells | (tryptase) | n= 160 | n = 151 | ||||
| none/few | 0 -5 | 19 | 0-30 | 25 | |||
| moderate | 6 -50 | 52 | 31 -100 | 59 | |||
| many | > 50 | 29 | > 100 | 16 | |||
| macrophages | (CD68) | n = 159 | |||||
| none/few | 0-50 | 28 | |||||
| moderate | 51 -150 | 50 | |||||
| many | > 150 | 22 | |||||
| NK cells | (CD56) | n = 159 | n = 136 | ||||
| none | 0 | 33 | 0 | 43 | |||
| moderate/many | > 0 | 67 | > 0 | 57 | |||
| T cells | (CD3) | n = 158 | n = 157 | ||||
| none/few | 0-55 | 27 | 0-300 | 20 | |||
| moderate | 56-105 | 36 | 301 - 500 | 51 | |||
| many | >105 | 37 | > 500 | 29 | |||
| CD4+ cells | n = 156 | n = 130 | |||||
| none/few | 0-30 | 43 | 0-20 | 24 | |||
| moderate | 31 -65 | 26 | 21 -110 | 50 | |||
| many | >65 | 31 | > 110 | 26 | |||
| CD8+ cells | n = 159 | n = 122 | |||||
| none/few | 0-15 | 26 | 0-135 | 77 | |||
| moderate | 16-75 | 47 | |||||
| many | >75 | 27 | > 135 | 23 | |||
Peritumoral infiltrate could not be reliably determined in all patients, because of the absence of invasive front in several tumor samples.
Results of univariate log rank analyses for the risk on local recurrence, the risk on distant metastases and the survival for the presence of inflammatory infiltrate and eosinophilic granuloytes.
| none/few | extensive | P | none/ few | moderate | extensive | P | |
| local recurrence rate | 6.9% | 3.4% | 0.03 | 7.4% | 4.8% | 2.8% | 0.10 |
| (2 year) | |||||||
| distant metastases | 23.8% | 8.2% | <0.0001 | 23.8% | 16.8% | 16.1% | 0.03 |
| rate (2 year) | |||||||
| cumulative survival | 79.1% | 92.0% | <0.0001 | 79.0% | 84.1% | 86.9% | 0.007 |
| (2 year) | |||||||
Median follow-up is 19.6 months, n = 1416.
Results of the multivariate Cox regression analysis for the risk on local recurrence, distant metastases and survival for the presence of inflammatory infiltrate and TNM classification.
| local recurrence | distant metastases | 2 year survival | ||||
| RR | 95%CI | RR | 95%CI | RR | 95%CI | |
| TNM I/II | 1.0 | 1.0 | 1.0 | |||
| TNM III/IV | 4.8 | 2.7-8.8 | 2.8 | 2.2-3.7 | 5.8 | 4.1-8.3 |
| none/few inflammatory cells | 1.0 | 1.0 | 1.0 | |||
| extensive inflammatory infiltrate | 1.7 | 0.7-4.3 | 2.6 | 1.5-4.6 | 2.4 | 1.2-4.5 |
Median follow up is 19.6 months, n = 1416. RR: relative risk, Cl: confidence interval
Correlation coefficients for all cell types (Pearsons' analysis).
| eo p (p) | NF i (i) | NF p (p) | MC i (i) | MC p (p) | MΦ i (i) | NK i (i) | NK p (p) | CD3 i | CD3 p | CD4 i | CD4 p | CD8 i | CD8 p | |
| 0.26* | 0.37* | 0.27* | 0.17 | 0.17 | Eo i (i) | |||||||||
| 0.21 | 0.24* | 0.23* | 0.18 | Eo p (p) | ||||||||||
| 0.63* | 0.19 | 0.16 | NF i | |||||||||||
| 0.19 | NF p (p) | |||||||||||||
| 0.29* | 0.17 | 0.27* | 0.19 | 0.25* | 0.22* | MC i (i) | ||||||||
| 0.16 | 0.19 | 0.22* | 0.24* | MC p | ||||||||||
| 0.25* | 0.30* | 0.19 | 0.22 | MΦ i | ||||||||||
| 0.20 | NK i | |||||||||||||
| 0.17 | NK p | |||||||||||||
| 0.38* | 0.36* | 0.30* | 0.16 | CD3 i | ||||||||||
| 0.23* | 0.26* | CD3 p | ||||||||||||
| 0.65* | CD4 i | |||||||||||||
| CD4 p | ||||||||||||||
| 0.76* | CD8 i |
Only the significant correlations are shown. The marked correlation coefficients (*) are significant with p values < 0.001, other correlations are significant at a level of p < 0.05. (n = 160). Eo:eosinophilic granuloytes, NF:neutrophilic granulocutes, MC:mast cells, MΦ:macrophages, p: peritumoral, i: intratumoral
Figure 1Mutual relations between the inflammatory cell types regardless of location. Relations depicted by bold arrows show a significant relationship with r ≥ 0.25. T-cells (CD3, not shown) show significant relations with all cell types (most strongly to CD4 and macrophages r ≥ 0.25).
Results of univariate log rank analyses for the risk on local recurrence, the risk on distant metastases and the survival.
| local recurrence % | distant metastases % | cumulative survival % | |||||||||||
| (2 year) | (2 year) | (2 year) | |||||||||||
| cell type | none/few | moderate | many | p-value | none/few | moderate | many | p-value | none/few | moderate | many | p-value | |
| eosinophils | |||||||||||||
| intratumoral | 18 | 26 | 34 | 0.45 | 30 | 54 | 56 | 0.08 | 72 | 67 | 62 | 0.94 | |
| peritumoral | 42 | 24 | 14 | 0.007* | 62 | 48 | 35 | 0.009* | 56 | 65 | 83 | 0.0008* | |
| neutrophils | |||||||||||||
| intratumoral | 35 | 23 | 23 | 0.42 | 46 | 49 | 47 | 0.85 | 61 | 68 | 73 | 0.66 | |
| peritumoral | 44 | - | 22 | 0.02* | 52 | - | 48 | 0.88 | 48 | - | 72 | 0.19 | |
| mast cells | |||||||||||||
| intratumoral | 42 | 23 | 20 | 0.17 | 65 | 47 | 39 | 0.08 | 45 | 74 | 71 | 0.006* | |
| peritumoral | 44 | 18 | 15 | 0.007* | 86 | 38 | 21 | <0.0001* | 43 | 78 | 73 | <0.0001* | |
| macrophages | |||||||||||||
| intratumoral | 41 | 25 | 9 | 0.03* | 63 | 50 | 28 | 0.03* | 56 | 70 | 75 | 0.006* | |
| peritumoral | 27 | 21 | 17 | 0.70 | 54 | 31 | 20 | 0.007* | 70 | 68 | 67 | 0.50 | |
| NK cells | |||||||||||||
| intratumoral | 36 | - | 20 | 0.03* | 50 | - | 47 | 0.58 | 57 | - | 73 | 0.15 | |
| peritumoral | 27> | - | 23 | 0.65 | 52 | - | 40 | 0.22 | 68 | - | 68 | 0.87 | |
| T cells (CD3) | |||||||||||||
| intratumoral | 35 | 29 | 13 | 0.08 | 76 | 42 | 32 | <0.0001* | 57 | 67 | 75 | 0.002* | |
| peritumoral | 25 | 23 | 25 | 0.67 | 63 | 41 | 47 | 0.02* | 60 | 70 | 69 | 0.17 | |
| CD4 T cells | |||||||||||||
| intratumoral | 33 | 31 | 10 | 0.01* | 48 | 47 | 46 | 0.55 | 66 | 60 | 78 | 0.21 | |
| peritumoral | 36 | 28 | 14 | 0.10 | 54 | 53 | 46 | 0.90 | 66 | 65 | 70 | 0.51 | |
| CD8 T cells | |||||||||||||
| intratumoral | 34 | 22 | 22 | 0.19 | 71 | 42 | 37 | 0.0005* | 58 | 73 | 69 | 0.01* | |
| peritumoral | 27 | - | 20 | 0.11 | 58 | - | 19 | 0.002* | 60 | - | 86 | 0.05 | |
The marked cell types (*) show a significant correlation with prognosis. Median follow up is 35.4 months, n = 160
Results of Cox regression analysis for local recurrence, distant metastases and survival.
| tested variables | cell types | cell types/ | TNM / | ||
| inflamm. | infiltrate | ||||
| RR | 95% CI | RR | 95% CI | ||
| peritumoral mast cells | |||||
| - none/few | 3.7 | 1.1 -12.8 | 1.9 | 0.5-7.1 | |
| -moderate | 1.3 | 0.4- 4.4 | 0.9 | 0.3-3.1 | |
| - many | 1.0 | 1.0 | |||
| inflammatory infiltrate | |||||
| -none/few | - | 1.0 | |||
| -extensive | 0.3 | 0.0-2.2 | |||
| n = 148 | TNM | ||||
| 33 events | - I/I I | - | 1.0 | ||
| -III/IV | 2.4 | 0.9-6.1 | |||
| peritumoral mast cells | |||||
| - none/few | 4.5 | 1.6-12.2 | 2.5 | 1.2-5.8 | |
| - moderate | 1.1 | 0.4-2.9 | 0.9 | 0.3-2.3 | |
| - many | 1.0 | 1.0 | |||
| intratumoral T cells (CD3) | |||||
| - none/few | 3.2 | 1.5-6.8 | 2.6 | 1.2-5.8 | |
| -moderate | 2.0 | 0.9-4.1 | 1.8 | 0.8-3.8 | |
| - many | 1.0 | 1.0 | |||
| inflammatory infiltrate | |||||
| - none/few | - | 1.0 | |||
| - extensive | 1.0 | 0.4-2.9 | |||
| n = 159 | TNM | ||||
| 65 events | -I/II | - | 1.0 | ||
| -III/IV | 4.4 | 1.9-9.9 | |||
| peritumoral eosinophils | |||||
| - none/few | 3.6 | 1.5-8.7 | 3.0 | 1.2-7.2 | |
| -moderate | 2.8 | 1.2-6.6 | 2.1 | 0.9-5.1 | |
| - many | 1.0 | 1.0 | |||
| peritumoral mast cells | |||||
| - none/few | 2.9 | 1.2-6.8 | 1.4 | 0.6-3.4 | |
| -moderate | 0.8 | 0.4-1.9 | 0.6 | 0.3-1.4 | |
| - many | 1.0 | 1.0 | |||
| inflammatory infiltrate | |||||
| - none/few | - | 1.0 | |||
| - extensive | 1.0 | 0.4-2.5 | |||
| n = 136 | TNM | ||||
| 59 events | - I/II | - | 1.0 | ||
| - III/IV | 2.9 | 1.4-6.2 | |||
Cell types are included in the multivariate analysis if their p-value was less than 0.05 in the univariate analysis (table 3). Cell types are reported here and included in the multivariate analysis with TNM classification and inflammatory infiltrate, if they were significant in the Cox' regression of the cell types forward step-wise applied.
Figure 2Kaplan-Meier survival curves for the development of distant recurrence showing the TNM independent effect of the three categories of intratumoral T cells (CD3), p = 0.0004
Figure 3Model of specific and nonspecific host response. The specific immune response are the T cells, the nonspecific immune response is formed by eosinophilic and neutrophilic granulocytes, mast cells, macrophages and NK cells.